Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 245

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria

Open access
De Pascale, Gennaro, Montini, Luca, Pennisi, Mariano Alberto, Bernini, Valentina, Maviglia, Riccardo, Bello, Giuseppe, Spanu, Teresa, Tumbarello, Mario, Antonelli, Massimo·2014·Critical Care

Abstract

Introduction: The high incidence of multidrug-resistant (MDR) bacteria among patients admitted to ICUs has determined an increase of tigecycline (TGC) use for the treatment of severe infections. Many concerns have been raised about the efficacy of this molecule and increased dosages have been proposed. Our purpose is to investigate TGC safety and efficacy at higher than standard doses. Methods: We conducted a retrospective study of prospectively collected data in the ICU of a teaching hospital in Rome. Data from all patients treated with TGC for a microbiologically confirmed infection were analyzed. The safety profile and efficacy of high dosing regimen use were investigated. Results: Over the study period, 54 patients (pts) received TGC at a standard dose (SD group: 50 mg every 12 hours) and 46 at a high dose (HD group: 100 mg every 12 hours). Carbapenem-resistant Acinetobacter.baumannii (bla OXA-58 and bla OXA-23 genes) and Klebsiella pneumoniae (bla KPC-3 gene) were the main isolated pathogens (n = 79). There were no patients requiring TGC discontinuation or dose reduction because of adverse events. In the ventilation-associated pneumonia population (VAP) subgroup (63 patients: 30 received SD and 33 HD), the only independent predictor of clinical cure was the use of high tigecycline dose (odds ratio (OR) 6.25; 95% confidence interval (CI) 1.59 to 24.57; P = 0.009) whilst initial inadequate antimicrobial treatment (IIAT) (OR 0.18; 95% CI 0.05 to 0.68; P = 0.01) and higher Sequential Organ Failure Assessment (SOFA) score (OR 0.66; 95% CI 0.51 to 0.87; P = 0.003) were independently associated with clinical failure. Conclusions: TGC was well tolerated at a higher than standard dose in a cohort of critically ill patients with severe infections. In the VAP subgroup the high-dose regimen was associated with better outcomes than conventional administration due to Gram-negative MDR bacteria.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/cc13858

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 245

Metadata

Authors
De Pascale, G., Montini, L., Pennisi, M. A., Bernini, V., Maviglia, R., Bello, G., Spanu, T., Tumbarello, M., & Antonelli, M.
Venue
Critical Care
Published
2014-05-05
Volume
18
Issue
3
Pages
R90-R90
ISSN
1364-8535 (ISSN-L)
OpenAlex
W2064648176
Cited by
245
References
3
FWCI
15.58
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. https://app.cochat.ai/papers/10.1186/cc13858
The paper
De Pascale, G., Montini, L., Pennisi, M. A., Bernini, V., Maviglia, R., Bello, G., Spanu, T., Tumbarello, M., & Antonelli, M. (2014). High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Critical Care. https://doi.org/10.1186/cc13858

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.